Fact CheckerSign in

NCT07750223Recruiting

Cognitive Effects of Hesperidin in Overweight/Obese Older Adults

A Randomized Controlled Trial of Hesperidin for Improving Cognitive Function in Overweight and Obese Middle-Aged and Older Adults

Source: ClinicalTrials.gov · Last updated 6 Aug 2026

Brief summary (registry, in English)

A randomized, double-blind, placebo-controlled trial was designed to test whether two doses of hesperidin (a natural flavonoid from citrus fruits) improve cognitive function in overweight and obese older adults. A total of 105 participants, aged 55-75 years with a BMI ≥24 kg/m² or elevated waist circumference, will be randomly assigned to one of three 10-week treatments: placebo, low-dose hesperidin (300 mg/day), or high-dose hesperidin (600 mg/day). The primary aim is to see if hesperidin supplementation enhances cognitive performance - specifically executive function, memory, and attention - and to explore any dose-response relationship. Secondary aims include examining changes in gut microbiota composition and related metabolites, as well as exploring potential mechanisms behind any observed effects. The findings are expected to provide scientific evidence on whether hesperidin could serve as a nutritional strategy to support cognitive health in this population.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
105 (estimated)
First submitted
17 Jul 2026
Start date
1 Feb 2026
Primary completion date
30 Mar 2027
Lead sponsor
Min Hou
Diseases
Obesity
NCT number
NCT07750223

What you commit to

  • Study type: Interventional
  • Planned participants: 105
  • From 1 Feb 2026 to the primary completion date, 30 Mar 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of weight-loss drugs or antidepressants (except statins) within recent months

Other illness

  • History of neurological diseases (Parkinson's, Alzheimer's, stroke, etc.)
  • Malignant tumors, severe liver/kidney/gastrointestinal diseases
  • Strict vegetarians, binge eating disorder, heavy alcohol consumption
  • Other conditions judged by investigators as unsuitable

Other

  • MMSE score \< 20
  • Participation in other intervention studies

Who the study is looking for

  • Age 55-75 years
  • BMI ≥ 24 kg/m² or waist circumference ≥ 90 cm (men) / ≥ 85 cm (women)
  • Willing to participate and sign informed consent

Age in the registry: 55 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Community Health Centers in Shanghai
Coordinator of this site? Confirm its status
ShanghaiChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.